HIGHLIGHTS
- who: Report et al. from the Reserve Hospital, Cuyahoga Falls, USA have published the Article: Review began 08/20/2022 Review ended 08/28/2022 Published 08/30/2022 u00a9 Copyright, in the Journal: (JOURNAL) of August/30,/2022
- what: In a multicenter randomized placebo-controlled phase three trial of lenvatinib with 392 participants with radioactive resistant differentiated thyroid cancer, the study showed a median progression-free survival of 18.3 months with a response rate of 64.8% when compared to the placebo arm .
SUMMARY
Thyroid cancer accounts for 3 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.